

ATTORNEY DOCKET NO. 14028.0292
Serial No. 09/383,695

Applicants wish to thank the Examiner for discussing the rejections and applicant's evidence in an interview on September 6, 2001. Applicants particularly appreciate the Examiner's flexibility in rescheduling the interview time. Applicant has attempted to provide with this Amendment information and amendments referred to in the interview.

I. AMENDMENTS

In the Specification

Please replace the paragraph beginning on page 1, line 6 with the following paragraph:

*Pl
Ab
E1*

--This application is a continuation of and claims priority to U.S.S.N. 08/843,409, filed April 15, 1997, now U.S. Patent No. 6,103,235, which is incorporated herein by reference in its entirety and which is a continuation-in-part of U.S.S.N., 08/739,703 filed October 29, 1996, now abandoned, and claims priority to U.S. Provisional Patent Application Serial Number 60/015,459, filed April 15, 1996, now abandoned, and U.S. Provisional Patent Application Serial Number 60/008,104, filed October 30, 1995, 1998, all of which are incorporated herein by reference.

On Page 67, delete Table 6 and insert therefor new Table 6 as follows on the next page:

ATTORNEY DOCKET NO. 14028.0292
Serial No. 09/383,695

67

Table 6. Sequences of oligonucleotide primers used for PCR amplification

Sequence ID Number	5'	Sequence	3'	Primers	RE sites
SEQ ID NO. 7	GACATCCAGATGACCCAGACC			P1 (UCHT1 VL5)	
SEQ ID NO. 8	CCTCCGAGCCACCGCTCCGCTCGCCTCCGCTCCCTTTTA TCTCCAGCTTG(T)GTC(G)CC			P2 (UCHT1 VL3)	
SEQ ID NO. 9	GCAGCGGAGGCGGTGGCTCGGGAGGGGAGGCTCGGAGGT GCAGCTTCAGCAGTCT			P3 (UCHT1 VL5)	
SEQ ID NO. 10	GCAAGCTTGAAAGACTGTGAGAGTGTGCCTTG			P4 (UCHT1 VH3)	Hind III
SEQ ID NO. 11	GTCTCTCAAAAGCTTATTGCC(T)GAGCTGCCTCCCAA			P5 (Hulgm-CH2)	Hind III
SEQ ID NO. 12	GCATCTAGATCAGTAGCAGGTGCCAGCTGTGT			P6 (Hulgm-CH4)	Xba I
SEQ ID NO. 13	CGGTCGACACCATGGAGACAGACACACTCTGTATGGGT ACTGCTGCTCTGGGTCCA			SP1 (<i>signal seq 1</i>)	Sal I
SEQ ID NO. 14	GTACTGCTGCTCTGGGTCCAGGTTCACACTGGGGACATCC AGATGACCCAG			SP2 (<i>signal seq 2</i>)	

RE: restriction enzyme.

Restriction sites appeared in the primers were underlined and bold.

The primers listed as SEQ ID NO:8 and SEQ ID NO:11 consisted of a mixture of the sequence without the nucleotide(s) in parentheses and the sequence (s) with the nucleotide(s) in parentheses replacing the immediately preceding nucleotide(s) in the sequence.

3